Trials / Unknown
UnknownNCT04356222
Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
Efficacy and Safety of Durvalumab Combined With Intrathecal Chemotherapy in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Hui Bu · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to observe the clinical efficacy and safety of Durvalumab combined with intrathecal chemotherapy in non-small cell lung cancer with leptomeningeal metastasis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Durvalumab | Intravenous infusion once every two weeks ,once 10mg/kg. |
| DRUG | methotrexate | Intrathecal chemotherapy specified dose on specified days |
Timeline
- Start date
- 2020-06-01
- Primary completion
- 2023-06-01
- Completion
- 2023-06-01
- First posted
- 2020-04-22
- Last updated
- 2020-05-27
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04356222. Inclusion in this directory is not an endorsement.